September 5, 2017

Mitchell R. McGill, PhD

Assistant Professor
 

Education

2017, Postdoctoral Fellowship, Washington University in St. Louis, Clinical chemistry and drug-induced liver disease
2013, PhD, University of Kansas, Toxicology
2007, BA, University of Missouri at Kansas City, Biology

Research Interests

  • Drug-induced liver injury
  • Biomarkers
  • Liver Regeneration
  • Clinical laboratory testing

Courses Taught

  • REGS 6013 FDA Regulations
  • ENVH 5202 Environmental Hazards Controls
  • ENVH 5221 Regulations in Environmental Health

Selected Recent Publications

McGill MR, James LP, McCullough SS, Moran JH, Mathews SE, Peterson EC, Fleming DP, Tripod ME, Vazquez JH, Kennon-McGill S, Spencer HJ, Dranoff JA. Short-Term Safety of Repeated Acetaminophen Use in Patients With Compensated Cirrhosis. Hepatol Commun. 2021. doi: 10.1002/hep4.1810. In press.

Clemens MM, Kennon-McGill S, Vazquez JH, Stephens OW, Peterson EA, Johann DJ, Allard FD, Yee EU, McCullough SS, James LP, Finck BN, McGill MR. Exogenous phosphatidic acid reduces acetaminophen-induced liver injury in mice by activating hepatic interleukin-6 signaling through inter-organ crosstalk. 2021. doi: 10.1016/j.apsb.2021.08.024. In press.

McGill MR, Jaeschke H. Biomarkers of mitotoxicity after acute liver injury: Further insights into the interpretation of glutamate dehydrogenase. J Clin Transl Res. 2021;7:61-65.

McGill MR, Hinson JA. The development and hepatotoxicity of acetaminophen: reviewing over a century of progress. Drug Metab Rev. 2020;52:472-500.

Clemens MM, Vazquez JH, Kennon-McGill S, McCullough SS, James LP, McGill MR. Pre-treatment twice with liposomal clodronate protects against acetaminophen hepatotoxicity through a pre-conditioning effect. Liver Res. 2020;4:145-152.

Complete Bibliography (Excluding 11 book chapters): https://www.ncbi.nlm.nih.gov/myncbi/10k4U8A4bmpAd/bibliography/public/